

ASX / MEDIA RELEASE

Extension of CEO and Managing Director's Contract

Brisbane, **Australia**, **2 May 2017** -- ResApp Health Limited (ASX:RAP) advises that Dr Tony Keating's contract of employment as CEO and Managing Director has been extended until 2 July 2019. The extension is on the same terms and conditions as Dr Keating's existing employment arrangements with the company.

The terms of Dr Keating's employment are set out in ResApp's 2016 Annual Report.

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has both adult and paediatric clinical studies underway with preliminary results demonstrating accurate diagnosis of pneumonia, asthma/viral wheeze, bronchiolitis, croup and upper respiratory tract infections in children as well as chronic obstructive pulmonary disease, asthma and pneumonia in adults. Markets for ResApp's technology include telehealth use through partnerships with telehealth service providers, emergency department and regular clinic use by healthcare providers, at-home use by consumers and working with global aid and humanitarian organisations to deliver tools for the developing world.

For more information on ResApp, visit www.resapphealth.com.au

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director and
Vice President, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au